<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aims  We aimed to assess the relative risk for <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Methods  In this study, 1112 patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (58% women, mean age 66.7 years, median duration of <z:mp ids='MP_0002055'>diabetes</z:mp> 10 years, 179 with previous history of <z:hpo ids='HP_0000820'>thyroid disease</z:hpo>) and 911 subjects without <z:mp ids='MP_0002055'>diabetes</z:mp> were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>Results  The gender-, age- and weight-adjusted relative risk (odds ratio) of newly identified <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in comparison with control subjects was 2.81 (1.77-4.48) </plain></SENT>
<SENT sid="3" pm="."><plain>This odds ratio was significant in patients over 65 years [4.02 (1.95-8.31)], as well as in both men [4.84 (1.58-14.80)] and women [2.60 (1.54-4.38)], in <z:mp ids='MP_0001261'>obese</z:mp> patients [2.56 (1.36-4.82)] and non-<z:mp ids='MP_0001261'>obese</z:mp> patients [3.11 (1.56-6.20)] and in individuals with [4.26 (1.73-10.46)] and without [2.93 (1.50-5.75)] thyroid autoantibodies </plain></SENT>
<SENT sid="4" pm="."><plain>Logistic regression analysis showed that newly diagnosed <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> was significantly and directly related not only with thyroid <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> [19.15 (8.73-42.01)], but also with the presence of <z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e> [2.85 (1.51-5.35)] and <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment [2.51 (1.28-4.92)] </plain></SENT>
<SENT sid="5" pm="."><plain>Conclusions  Our results favour screening for <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> in patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> older than 65 years, especially in the presence of <z:e sem="disease" ids="C1504375" disease_type="Disease or Syndrome" abbrv="">diabetic macroangiopathy</z:e> or treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi>. © 2012 The Authors </plain></SENT>
<SENT sid="6" pm="."><plain>Diabetic Medicine © 2012 <z:mp ids='MP_0002055'>Diabetes</z:mp> UK </plain></SENT>
</text></document>